Sivik Global Healthcare LLC Buys 22,000 Shares of BioNTech SE Sponsored ADR $BNTX

Sivik Global Healthcare LLC bought a new position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 22,000 shares of the company’s stock, valued at approximately $2,163,000. BioNTech accounts for approximately 1.3% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 28th biggest holding.

A number of other large investors also recently added to or reduced their stakes in BNTX. Flossbach Von Storch SE bought a new stake in BioNTech in the second quarter worth $207,142,000. First Trust Advisors LP grew its stake in shares of BioNTech by 116.0% during the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after buying an additional 451,124 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of BioNTech in the second quarter worth about $39,385,000. SEB Asset Management AB purchased a new position in shares of BioNTech in the first quarter worth about $17,804,000. Finally, Bank of America Corp DE lifted its stake in shares of BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after acquiring an additional 166,432 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 5.5%

Shares of NASDAQ:BNTX traded down $5.32 during midday trading on Tuesday, hitting $90.52. 1,081,900 shares of the stock traded hands, compared to its average volume of 1,089,696. The stock has a market capitalization of $22.89 billion, a PE ratio of -11.57 and a beta of 1.25. The business’s 50 day moving average is $99.24 and its two-hundred day moving average is $95.29. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The business’s revenue for the quarter was down 59.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.60) earnings per share. As a group, research analysts forecast that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several analyst reports. Wall Street Zen cut BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Argus initiated coverage on BioNTech in a research note on Thursday, October 8th. They issued a “hold” rating on the stock. UBS Group reiterated a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Friday, October 2nd. Finally, Morgan Stanley dropped their price objective on BioNTech from $115.00 to $114.00 and set an “overweight” rating for the company in a research note on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $125.69.

Insider Buying and Selling

In other BioNTech news, CEO Ugur Sahin sold 72,000 shares of the company’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the completion of the transaction, the chief executive officer owned 108,209 shares of the company’s stock, valued at $10,521,161.07. This represents a 39.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 807,209 shares of company stock worth $79,246,837. Corporate insiders own 19.20% of the company’s stock.

BioNTech Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.